resisttb
- May 26
- 1 min read

Why is a curable disease allowed to kill millions?

John Green, the author of several books and a longtime supporter of Partners in Health, discusses his time visiting Sierra Leone’s Lakka Government Hospital, a tuberculosis treatment center. He talks about Henry, a 16-year old boy cured from multi-drug resistant TB as the first Sierra Leonean patient to receive a newly designed treatment regimen that included bedaquiline in 2021. With J&J's patent on bedaquiline ending soon, John Green provides us with a call to action to urge J&J to relinquish its extended patent claims and make the drug more widely accessible and affordable. Read more here.

Recent Posts

See All

International consensus highlights the importance of molecular testing for MDR-TB

A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibio

Sweet advance for treatment of children with multi-drug resistant TB

Children with multi-drug resistant tuberculosis (MDR-TB) undergo months of life-saving treatment including many doses of foul-tasting medications, which caregivers often struggle to prepare and admini

New safer and shorter drug-resistant TB treatment must be scaled up

Médecins Sans Frontières (MSF) calls on governments and donors to speed up access to new, shorter, safer and more effective treatments for drug-resistant tuberculosis (DR-TB). MSF joined the World Hea